Gossamer Bio
GOSS
99 hedge funds and large institutions have $74.4M invested in Gossamer Bio in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 43 reducing their positions, and 25 closing their positions.
105% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $584K
11% less funds holding
Funds holding: 111 → 99 (-12)
16.8% less ownership
Funds ownership: 81.78% → 64.97% (-17%)
24% less capital invested
Capital invested by funds: $97.9M → $74.4M (-$23.5M)
48% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 25
56% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.2M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$2.49M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$1.36M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.06M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$572K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.7M |
| 2 |
BlackRock
New York
|
-$3.59M |
| 3 |
E
Ergoteles
New York
|
-$2.13M |
| 4 |
Walleye Capital
New York
|
-$2.03M |
| 5 |
HF
HRT Financial
New York
|
-$1.95M |
GOSS Hedge Fund Activity: Q2 2023 in Review
99 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q2 2023, worth a combined $74.4M — down 24% from $97.9M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of GOSS and 13 opened new positions — a net loss of 12 holders — while 43 trimmed existing stakes and 19 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $4.2M. The largest seller was Vanguard Group, cutting an estimated $3.7M.
- 99 institutional investors held Gossamer Bio (GOSS) as of Q2 2023, down from 111 in Q1 2023.
- Funds reported $74.4M of Gossamer Bio stock for Q2 2023, down 24% quarter-over-quarter.
- 13 funds opened new Gossamer Bio positions in Q2 2023 and 25 closed out, a net change of -12 holders.
- The largest Gossamer Bio buyer in Q2 2023 was Opaleye Management, an estimated $4.2M added.
- The largest Gossamer Bio seller in Q2 2023 was Vanguard Group, an estimated $3.7M sold.
Based on aggregated 13F filings for Q2 2023.